Drug intelligence / Profile preview

atorvastatin + colchicine

Development stage
Phase 2
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

**Atorvastatin + colchicine** is a combination of two small-molecule drugs: atorvastatin, a statin used primarily for lipid lowering and cardiovascular risk reduction, and colchicine, an anti-inflammatory agent mainly used to treat gout and pericarditis. Atorvastatin works via competitive inhibition of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, resulting in decreased cholesterol production and reduced risk of atherosclerotic events. Colchicine acts primarily by binding to tubulin, inhibiting microtubule polymerization and thus modulating leukocyte activity and inflammatory responses. This combination is of particular clinical interest in patients with both cardiovascular disease and indications for colchicine (e.g., gout, pericarditis) or following recent evidence for colchicine in atherosclerotic risk reduction. However, both drugs are metabolized by CYP3A4 and are substrates for P-glycoprotein, leading to significant drug-drug interaction risk, notably increased likelihood of myopathy and rhabdomyolysis due to elevated plasma levels when administered together[1][2][3].

02

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on atorvastatin + colchicine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on atorvastatin + colchicine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call